ALK Gene Rearrangemnet in Lung Adenocarcinoma

Objective: To assess the frequency of ALK gene rearrangement among patients presenting with lung adenocarcinoma at tertiary care hospital of Karachi, Pakistan. Study Design: Prospective longitudinal study Place and Duration of Study: Department of Medical Oncology, Jinnah Postgraduate Medical Colleg...

Full description

Saved in:
Bibliographic Details
Published in:Pakistan Armed Forces medical journal 2023-08, Vol.73 (SUPPL-1), p.S111-114
Main Authors: Rani, Berkha, Ghulam Haider, Sana Sehar, Versha Rani Rai, Fnu Raja, Maliha Ashfaq
Format: Article
Language:English
Subjects:
Adenocarcinoma
Age groups
Asian people
Cancer
Crizotinib
Ethnicity
Females
Gender
Genetic aspects
Genetic testing
Histology
Hybridization
Kinases
Lung cancer
Lung cancer, Non-small cell
Males
Mutation
Oncology
Population
Religion
Tumors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: To assess the frequency of ALK gene rearrangement among patients presenting with lung adenocarcinoma at tertiary care hospital of Karachi, Pakistan. Study Design: Prospective longitudinal study Place and Duration of Study: Department of Medical Oncology, Jinnah Postgraduate Medical College Karachi, Pakistan from May 2019 Mar 2020. Methodology: Total 185 patients with confirmed diagnosis of stage IV lung adenocarcinoma who were unresectable and metastatic of age 20-75 years of either gender were included in the study using non-probability consecutive sampling technique. Patients were subjected for ALK mutation analysis using fluorescent in situ hybridization technique. Results: Out of 185 patients, the ALK rearrangements were found positive in 27 tumors whereas it was negative in 158 tumors. Among ALK positive cases, majority of the patients were of aged less than 50 years (n=18, 66.7%).The statistically significant difference was found between age and ALK gene rearrangement (p0.05). Conclusion: The results showed positive rearrangement of ALK gene in 15% of the patients which is in contrast to 7% patients found in western studies. ALK gene testing has become standard of care in patients of adenocarcinoma who are EGFR negative so that treatment like ALK gene inhibitors such as alectinib, brigatinib, ceritinib, crizotinib, and lorlatinib can be tailored accordingly.
ISSN:0030-9648
2411-8842
DOI:10.51253/pafmj.v73iSUPPL-1.5302